Skip to main content
. 2019 Mar 15;10:186. doi: 10.3389/fgene.2019.00186

Table 4.

Meta-analysis of miR-196a-2 rs11614913 and cancer risk.

Homozygote (TT vs. CC) Heterozygote (CT vs. CC) Dominant (TT+CT vs. CC) Recessive (TT vs. CT+CC) Allelic (T vs. C)
Groups Cases/Controlsa ORb
(95% CI) 		Pc I2 ORb
(95% CI) 		Pc I2 ORb
(95% CI) 		Pc I2 ORb
(95% CI) 		Pc I2 ORb
(95% CI) 		Pc I2
All studies 41,673/49,570 0.88 (0.79–0.98) <1e−4 77.1 1.00 (0.93–1.08) <1e−4 70.4 0.97 (0.89–1.05) <1e−4 76.8 0.89 (0.83–0.96) <1e−4 68.6 0.95 (0.90–1.00) <1e−4 78.9
Controls in HWE d 36,620/42,501 0.88 (0.80–0.98) <1e−4 74.6 1.00 (0.93–1.08) <1e−4 66.3 0.97 (0.89–1.04) <1e−4 74.3 0.88 (0.82–0.95) <1e−4 67.7 0.94 (0.89–0.99) <1e−4 77.3
QUALITY
High (>8) 38,503/46,453 0.87 (0.77–0.97) <1e−4 78.1 0.98 (0.91–1.06) <1e−4 69.6 0.94 (0.87–1.03) <1e−4 76.7 0.88 (0.81–0.95) <1e−4 70.9 0.93 (0.88–0.99) <1e−4 79.7
Low (≤8) 3170/3117 098 (0.70–1.38) <1e−4 68.3 1.09 (0.80–1.48) <1e−4 71.9 1.07 (0.80–1.44) <1e−4 74 0.97 (0.79–1.18) 0.025 44.5 1.03 (0.87–1.22) <1e−4 71
GENOTYPING
PCR–RFLP 15,282/18,081 0.85 (0.69–1.04) <1e−4 81.4 0.96 (0.83–1.11) <1e−4 77.8 0.93 (0.80–1.09) <1e−4 82.9 0.89 (0.78–1.00) <1e−4 71.1 0.93 (0.85–1.02) <1e−4 84
Others 26,391/31,489 0.91 (0.82–1.01) <1e−4 70.3 1.03 (0.96–1.11) <1e−4 57.2 1.00 (0.92–1.07) <1e−4 64.8 0.89 (0.82–0.96) <1e−4 66.5 0.96 (0.91–1.01) <1e−4 70.7
ETHNICITIES
Asian 33,039/38,092 0.86 (0.77–0.97) <1e−4 76.4 1.0 (0.92–1.09) <1e−4 68.3 0.96 (0.88–1.05) <1e−4 74.1 0.87 (0.81–0.93) <1e−4 68.2 0.93 (0.89–0.98) <1e−4 76.4
Caucasian 7273/9737 0.86 (0.63–1.18) <1e−4 81.1 0.92 (0.75–1.13) <1e−4 78.3 0.91 (0.72–1.15) <1e−4 85.1 0.92 (0.73–1.15) <1e−4 71.2 0.94 (0.78–1.13) 0.00 86.5
Africans/mixed 1361/1741 1.40 (0.89–2.21) 0.058 53.1 1.27 (0.87–1.86) 0.01 63.1 1.31 (0.95–1.80) 0.02 60.5 1.24 (0.77–2.0) 0.05 54.3 1.21 (0.99–1.49) 0.047 55.3
CANCER CATEGORIES
GI 16,537/21,226 0.87 (0.71–1.06) <1e−4 83.7 0.96 (0.84–1.10) <1e−4 76.8 0.93 (0.80–1.08) <1e−4 82.9 0.90 (0.79–1.02) <1e−4 76.1 0.94 (0.85–1.03) <1e−4 85
HNC 4,865/5,648 1.05 (0.76–1.46) 0.001 68.9 1.10 (0.79–1.54) <1e−4 75 1.08 (0.78–1.49) <1e−4 76.2 0.99 (0.90–1.09) 0.085 42.3 1.01 (0.85–1.21) 5e−4 71.2
GyC 1,394/1,573 0.85 (0.53–1.36) 0.042 56.6 1.02 (0.66–1.58) 0.061 52.5 0.96 (0.61–1.50) 0.030 59.5 0.80 (0.68–0.95) 0.346 10.8 0.88 (0.79–0.98) 0.089 47.6
HM 1,347/2,571 0.71 (0.34–1.49) 1e−4 80.4 0.91 (0.77–1.09) 0.071 50.7 0.79 (0.52–1.19) 0.008 67.5 0.80 (0.42–1.51) 0.00 80.2 0.83 (0.57–1.21) 0.00 80.5
UG 3,599/4,356 0.98 (0.74–1.30) 0.002 61.5 1.19 (0.96–1.48) 0.003 60.5 1.15 (0.94–1.42) 0.002 61.3 0.91 (0.70–1.19) 0.001 63.8 1.047 (0.91–1.19) 0.002 61.5
Others 13,710/16,018 0.86 (0.76–0.98) <1e−4 57.2 0.98 (0.88–1.10) <1e−4 56.7 0.95 (0.85–1.06) <1e−4 62.4 0.87 (0.79–0.95) 0.003 44.6 0.94 (0.87–1.00) <1e−4 62.3
CANCER TYPES
BC e 7,401/8,828 0.85 (0.71–1.01) 0.001 56.4 0.93 (0.81–1.08) 0.002 53.3 0.91 (0.78–1.06) 2e−4 60.8 0.89 (0.79–1.01) 0.024 43 0.93 (0.84–1.02) <1e−4 62.7
HCCe 5,401/6,326 0.73 (0.57–0.94) <1e−4 69.5 0.92 (0.78–1.09) 0.002 55.2 0.87 (0.73–1.04) <1e−4 64.7 0.79 (0.66–0.95) 2e−4 63.2 0.88 (0.78–0.98) <1e−4 68.8
GC 4,664/6,385 0.80 (0.47–1.36) <1e−4 90.3 0.81 (0.56; 1.15) <1e−4 88.6 0.80 (0.53–1.20) <1e−4 92.1 0.91 (0.65–1.29) <1e−4 81.5 0.88 (0.66–1.17) <1e−4 92.4
CRCe 2,567/4,211 1.21 (0.65–2.27) <1e−4 87.6 1.12 (0.71–1.75) <1e−4 81.1 1.13 (0.70–1.85) <1e−4 84.7 1.08 (0.83–1.42) <1e−4 78.6 1.06 (0.86–1.29) <1e−4 86.4
LC e 4,453/4,932 0.86 (0.63–1.17) 0.009 60.2 1.01 (0.91–1.12) 0.057 46.9 1.00 (0.82–1.21) 0.015 57.7 0.82 (0.65–1.03) 0.012 59 0.93 (0.81–1.08) 0.004 64.5
BlC 1,390/1,562 0.75 (0.41–1.39) 0.060 59.3 1.01 (0.53–1.89) 0.017 70.4 0.97 (0.62–1.52) 0.088 54 0.77 (0.30–1.97) 3e−4 84.3 0.94 (0.68–1.29) 0.036 64.7
PC 868/1,345 1.01 (0.74–1.39) 0.396 1.8 1.27 (0.83–1.95) 0.057 56.4 1.23 (0.83–1.83) 0.069 54 0.94 (0.71–1.24) 0.485 0 1.06 (0.93–1.22) 0.241 27.1
OC 2,138/2,957 0.98 (0.49–1.95) <1e−4 81.6 1.14 (0.57–2.29) <1e−4 82.3 1.07 (0.53–2.12) <1e−4 85 0.87 (0.76–1.00) 0.189 32.8 0.96 (0.66–1.40) <1e−4 82
OvC 843/1,100 0.81 (0.28–2.37) 0.023 68.4 1.03 (0.38–2.78) 0.029 66.6 0.95 (0.34–2.63) 0.017 70.4 0.73 (0.60–0.90) 0.332 12.1 0.88 (0.58–1.32) 0.050 61.6
ESCC 3,492/4,376 0.85 (0.49–1.47) <1e−4 82.4 1.04 (0.83–1.31) 0.039 57.2 0.99 (0.76; 1.29) 0.008 67.8 0.81 (0.51–1.28) <1e−4 81.3 0.94 (0.76–1.16) 6e−4 76.8
Others 8,214/11,444 0.98 (0.80–1.20) <1e−4 68.5 1.05 (0.91–1.22) <1e−4 61.5 1.03 (0.88–1.21) <1e−4 68.3 0.96 (0.83–1.11) <1e−4 61.7 1.00 (0.89–1.11) <1e−4 72

The overall, HWD-sensitivity and subgroup analyses.

a

n represents number of cases and controls in each group.

b

Pooled ORs and 95% confidence intervals.

c

P-value of the heterogeneity test.

d

Meta-analysis of all studies excluding those with the control group not in HWE.

e

These subgroups were found to be influenced by departure from HWE. Please consult with the Supplementary Table S2 for details on HWD sensitivity and adjustments.

GI, cancers of digestive system; HNC, Head and neck carcinoma; GyC, Gynecologic cancers; HM, Hematological malignancies; UG, Urogenital cancers; BC, breast cancer; HCC, Hepatocellular cancer; GC, gastric cancer; CRC, colorectal cancer; LC, lung cancer; BlC, bladder cancer; PC, prostate cancer; OC, Oral cancer; OvC, ovarian cancer; ESCC, esophageal squamous cell carcinoma.

Significant associations are shown in boldface.